Today's Trend
Evolent Health, Inc. (NYSE: EVH) shares have been moving higher after the company’s first-quarter 2026 update and several bullish analyst reactions, even though revenue came in below expectations.
- Evolent’s Q1 EPS loss of $0.02 was better than the expected loss of $0.05, suggesting profitability trends were slightly better than analysts feared. Evolent Health Q1 2026 Earnings Call Transcript
- Needham raised its price target on EVH from $4.00 to $5.00 and reiterated a buy rating, pointing to additional upside from current levels. Needham Price Target Raise
- The company also lifted full-year 2026 revenue guidance to a range of $2.4 billion to $2.6 billion, which signals management expects stronger business performance ahead. Evolent Announces First Quarter 2026 Results
- Revenue of $496.25 million missed Wall Street’s $534.0 million estimate, so investors are weighing the top-line shortfall against better-than-expected earnings and upbeat guidance. Evolent Health Misses Q1 Revenue Estimates
Overall, EVH appears to be trading higher because investors are focusing on the earnings beat, raised guidance, and analyst upgrades more than the revenue miss.